TD Cowen analyst Brendan Smith maintained a Buy rating on Ginkgo Bioworks Holdings (DNA – Research ... and fragrance industry. Its platform provides equipment, software, robotic automation, and tools ...

Ginkgo Bioworks Holdings, Inc. , which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September ...

Ginkgo Bioworks has been busy ... and RNA therapies. The platform is designed to deliver more effective specific and durable genetic drugs, according to the company. Last on the list of ...

Ginkgo Bioworks Holdings, Inc. ( (DNA)) has released its Q3 earnings ... Strategically, the company continues to focus on expanding its cell engineering platform, adding 25 new programs and securing ...

BOSTON, Nov. 5, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it ...

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and ...

Every investor in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 48% to be ...

Presentation and Q&A session scheduled for post-market on Tuesday, November 12, 2024 The presentation details and webcast link will be available on Ginkgo's investor relations website at https ...

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we ...